Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:811076rdf:typepubmed:Citationlld:pubmed
pubmed-article:811076lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:811076lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:811076lifeskim:mentionsumls-concept:C0014549lld:lifeskim
pubmed-article:811076lifeskim:mentionsumls-concept:C0009011lld:lifeskim
pubmed-article:811076lifeskim:mentionsumls-concept:C0014547lld:lifeskim
pubmed-article:811076lifeskim:mentionsumls-concept:C0205246lld:lifeskim
pubmed-article:811076lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:811076lifeskim:mentionsumls-concept:C0687760lld:lifeskim
pubmed-article:811076lifeskim:mentionsumls-concept:C0175668lld:lifeskim
pubmed-article:811076lifeskim:mentionsumls-concept:C0699317lld:lifeskim
pubmed-article:811076lifeskim:mentionsumls-concept:C0701472lld:lifeskim
pubmed-article:811076pubmed:dateCreated1976-2-2lld:pubmed
pubmed-article:811076pubmed:abstractTextIn a controlled clinical investigation based on 14 patients with focal seizures and 3 patients with secondary generalized grand mal epilepsy, all with insufficient response to conventional anti-epileptic treatment, clonazepam (Rivotril(R)) combined with previous anti-epileotic drugs was compared with placebo combined with the same drugs. The trial was singleblind cross-over with sequential analyses. With a daily dose, depending upon age, of usually 3-6 mg, the antiepileptic effect of Clonazepam was significantly superior to placebo and was estimated as remarkably good. Side-effects in the form of somnolence, fatique, drowsiness and co-ordination disturbances occurred in most of the patients but subsided spontaneously or could be managed by slow increase or slight reduction in dosage.lld:pubmed
pubmed-article:811076pubmed:languageenglld:pubmed
pubmed-article:811076pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:811076pubmed:citationSubsetIMlld:pubmed
pubmed-article:811076pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:811076pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:811076pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:811076pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:811076pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:811076pubmed:statusMEDLINElld:pubmed
pubmed-article:811076pubmed:issn0065-1427lld:pubmed
pubmed-article:811076pubmed:authorpubmed-author:Birket-SmithE...lld:pubmed
pubmed-article:811076pubmed:authorpubmed-author:MikkelsenBBlld:pubmed
pubmed-article:811076pubmed:authorpubmed-author:VestermarkSSlld:pubmed
pubmed-article:811076pubmed:authorpubmed-author:HomeGGlld:pubmed
pubmed-article:811076pubmed:authorpubmed-author:MonkC JCJlld:pubmed
pubmed-article:811076pubmed:authorpubmed-author:OlsenP ZPZlld:pubmed
pubmed-article:811076pubmed:issnTypePrintlld:pubmed
pubmed-article:811076pubmed:volume60lld:pubmed
pubmed-article:811076pubmed:ownerNLMlld:pubmed
pubmed-article:811076pubmed:authorsCompleteYlld:pubmed
pubmed-article:811076pubmed:pagination55-61lld:pubmed
pubmed-article:811076pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-H...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-A...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-A...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-C...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-C...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-P...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-P...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-F...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-M...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-A...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-P...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-E...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-M...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-E...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-C...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-D...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-B...lld:pubmed
pubmed-article:811076pubmed:meshHeadingpubmed-meshheading:811076-C...lld:pubmed
pubmed-article:811076pubmed:year1975lld:pubmed
pubmed-article:811076pubmed:articleTitleA controlled trial on clonazepam INN (Ro 5-4023, Rivotril (R)) in the treatment of focal epilepsy and secondary generalized grand mal epilepsy.lld:pubmed
pubmed-article:811076pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:811076pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:811076pubmed:publicationTypeControlled Clinical Triallld:pubmed